Clinical Trials Directory

Trials / Completed

CompletedNCT05417659

Glycogen and Appetite

The Effect of Suppression of Adipose Lipolysis on GLP-1 and Energy Intake in Men and Women

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
15 (actual)
Sponsor
University of Bath · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

Obesity is the outcome of chronic excessive energy intake and reduced energy expenditure leading to energy imbalance. It is a risk factor for many preventable diseases such as metabolic disease and its consequences such as type 2 diabetes and cardiovascular disease. Sedentary adults have been shown to have an increased appetite in excess of energy requirements and adults who are more active are able to better regulate energy intake. It is thought that carbohydrate availability and specifically hepatic glycogen utilisation during exercise is a regulator of appetite. However, the majority of research so far does not support this theory, potentially due to research not examining the tissue-specific link between glycogen use and appetite. The aim of this study is to assess whether altering substrate utilisation during exercise by suppressing lipolysis influences GLP-1 levels and caloric intake post exercise. Additionally, the study will explore if there is a tissue specific link between substrate utilisation and post exercise energy intake and examine potential sex differences.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTExercise plus carbohydrateA high carbohydrate drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise.
DIETARY_SUPPLEMENTExercise plus niacinA dose of niacin to be consumed 30 minutes prior to exercise, at onset of exercise and 30 minutes into exercise.
OTHERPlaceboA placebo drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise and placebo tablets to be consumed 30 minutes prior to exercise, at the onset of exercise and 30 minutes into exercise.

Timeline

Start date
2022-10-10
Primary completion
2024-03-15
Completion
2024-08-30
First posted
2022-06-14
Last updated
2025-03-27

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT05417659. Inclusion in this directory is not an endorsement.